GSTM1 and anemia: The critical role of anemia in determining MF prognosis is underscored by its inclusion in key prognostic models, such as the Dynamic International Prognostic Scoring System (DIPSS) (15), which evaluates risk based on anemia (Hb <10 g/dL), age >65 years, constitutional symptoms, leukocyte count >25 x 10^9/L, and peripheral blood blasts ≥1%.